Anti-phospho PDHE1-A type I (Ser300)

Analysis Note

ControlDichloroacetate untreated and treated HEK 293 cell lysates

Application

Immunocytochemistry Analysis: A 1:500 dilution from a representative lot detected PDHE1-A type I in dichloroacetate untreated and treated HEK 293 cells.

This Anti-phospho PDHE1-A type I (Ser300) Antibody is validated for use in WB, IC for the detection of phospho PDHE1-A type I (Ser300).

General description

In many organisms, the pyruvate dehydrogenase complex catalyzes the overall, irreversible conversion of pyruvate to acetyl-CoA and CO2 in the aerobic, energy-generating pathways, in addition to serving as a key regulator for cardiac substrate selection. It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3). PDH is regulated by both pyruvate dehydrogenase kinase (PDK)-mediated phosphorylation and feedback inhibition.

Immunogen

KLH-conjugated linear peptide corresponding to human PDHE1-A type I phosphorylated at Ser300.

Epitope: Phosphorylated Ser300

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Quality

Evaluated by Western Blot in dichloroacetate untreated and treated HEK 293 cell lysates.

Western Blot Analysis: 0.5 µg/mL of this antibody detected PDHE1-A type I on 10 µg of dichloroacetate untreated and treated HEK 293 cell lysates.

Specificity

This antibody recognizes PDHE1-A type I phosphorylated at Ser300.

Target description

~43 kDa observed